Rosetta Genomics' 2011 Revenues Fall 63 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics said in a regulatory document that revenues for full-year 2011 dropped 63 percent year over year.

In its Form 10-K filed with the US Securities and Exchange Commission today, the Israel-based molecular diagnostics firm said that revenues for 2011 came in at $103,000, down from $279,000 in 2010, due primarily to its former distributor in the US ending sales of Rosetta products in late 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.